STRATEC Biomedical AG / Key word(s): Results Forecast/Change in Forecast
12.07.2013 15:47
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC reports contract discontinuation and updates guidance
Birkenfeld, July 12, 2013
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today
reports that the company has been informed by a customer on July 11, 2013
that a contract announced on December 14, 2010 concerning the development
and supply of an analyzer system will no longer be continued due to a
strategic change on the part of this customer. STRATEC expects the impact
on future budgeted development and production sales to be in the
double-digit million euro range. The amount of compensation expected to be
paid to STRATEC is currently under negotiation.
Excluding this potential compensation payment, STRATEC expects to generate
sales of between Euro 127 million and Euro 138 million in the 2013
financial year, with an EBIT margin of between 14.0% and 15.5%. Given the
other analyzer systems currently in development that are expected to be
launched by customers between 2014 and 2016, the company expects to
generate average annual sales growth of 8% to 12% through to 2017 based on
2013 sales figures. This company forecast replaces the previously valid
forecast.
As planned, the company's interim report as of June 30, 2013 will be
published on July 23, 2013.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
About STRATEC:
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com
12.07.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: STRATEC Biomedical AG: STRATEC reports contract discontinuation and updates guidance
| Source: EQS Group AG